A Phase 2 interventional study of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes and Normal Saline (0.9% NaCl) in Androgenetic Alopecia (AGA), sponsored by Zhang Han. Recruiting at 1 site in China. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Zhang Han · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to learn if local scalp injection of human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) can treat androgenetic alopecia (AGA) in male patients with AGA.
The main question it aims to answer is:
Does hUCMSC-Exos injection improve hair regrowth compared with placebo?
Researchers will compare hUCMSC-Exos injection to placebo injection to see if hUCMSC-Exos leads to superior efficacy in hair follicle regeneration, as measured by changes in hair density, hair thickness, and patient-reported outcomes.
Participants will:
Receive randomized, double-blinded local scalp injections of either hUCMSC-Exos or placebo
Attend scheduled follow-up visits for hair assessment and safety monitoring
Undergo photography, trichoscopy, and complete quality-of-life or psychosocial burden questionnaires as applicable
Androgenetic alopecia (AGA) is a chronic, progressive condition characterized by gradual miniaturization of hair follicles in a patterned distribution, primarily influenced by genetic susceptibility and androgen-mediated signaling pathways. The condition involves disruption of the hair cycle, particularly shortening of the anagen phase and progressive conversion of terminal hair follicles into vellus-like follicles, ultimately resulting in visible hair thinning and reduced hair density. In addition to its dermatological manifestations, AGA is associated with significant psychological burden, including decreased self-confidence and impaired quality of life.
Current pharmacological interventions mainly aim to slow disease progression rather than fully restore follicular function. However, their limited efficacy and dependency on continuous administration highlight the unmet need for regenerative and disease-modifying therapeutic strategies.
Mesenchymal stem cell-derived exosomes (MSC-Exos) represent a novel class of cell-free biologics with regenerative and immunomodulatory properties. These nano-sized extracellular vesicles contain bioactive molecules such as proteins, lipids, and nucleic acids, which mediate intercellular communication and regulate multiple biological processes. Among different MSC sources, human umbilical cord-derived MSCs are considered to possess advantageous biological characteristics, including higher proliferative capacity, lower immunogenicity, and more stable paracrine activity, making their exosomes particularly suitable for clinical translation.
Experimental studies have demonstrated that MSC-Exos may influence hair follicle biology through multiple complementary mechanisms, including modulation of dermal papilla cell activity, regulation of signaling pathways involved in follicular cycling, enhancement of vascular support within the perifollicular environment, and attenuation of local inflammatory responses. These combined effects may contribute to the reactivation of dormant follicles and support the transition of hair follicles into the anagen growth phase.
This clinical investigation is designed to translate these preclinical findings into a controlled human study setting, aiming to systematically evaluate the therapeutic potential of hUCMSC-derived exosomes for hair regeneration. The study will generate evidence regarding both clinical efficacy and safety profile, providing foundational data for future development of exosome-based regenerative therapies in androgenetic alopecia.
Participants must meet all of the following criteria to be eligible for enrollment:
Exclusion Criteria
Participants meeting any of the following criteria will be excluded:
Drug: Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes
Other: Normal Saline (0.9% NaCl)
Sterile exosome suspension derived from human umbilical cord mesenchymal stem cells (hUCMSC-Exos). Administered via intradermal scalp injection at 0.05 mL per point, 1 cm spacing, approximately 4 mm depth. Treatment repeated once every 4 weeks for a total of 3 sessions.
Sterile 0.9% normal saline injection. Administered via intradermal scalp injection using the same protocol as the experimental group: 0.05 mL per point, 1 cm spacing, approximately 4 mm depth, once every 4 weeks for a total of 3 sessions.
Change in Hair Density From Baseline to Week 24
Hair density (hairs/cm²) within a predefined target scalp area will be assessed using digital trichoscopy.
Time frame: Baseline to Week 24
Change in Modified Global Photographic Assessment (MGPA) Score From Baseline to Week 24
Global scalp photographs will be evaluated by blinded investigators using the Modified Global Photographic Assessment (MGPA) scale to assess overall improvement in hair growth.
Time frame: Baseline to Week 24
Change in Hair Density From Baseline to Week 12
Hair density changes within the predefined target area measured by digital trichoscopy.
Time frame: Baseline to Week 12
Change in Modified Global Photographic Assessment (MGPA) Score From Baseline to Week 12
Assessment of global hair growth improvement using standardized photography and MGPA scoring.
Time frame: Baseline to Week 12
Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 24
Evaluation of treatment-related quality of life improvement using the Dermatology Life Quality Index questionnaire.
Time frame: Baseline to Week 24
Change in Mean Hair Shaft Diameter From Baseline to Week 24
Mean hair shaft diameter will be measured using digital trichoscopic analysis.
Time frame: Baseline to Week 24
Change in Hair Type Proportions From Baseline to Week 24
Percentage changes in vellus hairs, intermediate hairs, and terminal hairs within the target scalp area.
Time frame: Baseline to Week 24
Subject Satisfaction Score at Week 24
Participant-reported satisfaction regarding overall hair growth improvement and treatment outcomes.
Time frame: Week 24
Investigator Satisfaction Assessment at Week 24
Overall investigator-rated assessment of treatment response and cosmetic improvement.
Time frame: Week 24
Plan to share: Undecided — Individual participant data (IPD) sharing has not yet been determined. Data sharing policies will be considered after study completion in accordance with institutional regulations, ethical requirements, and participant privacy protection.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.